Literature DB >> 880564

Clinical and prognostic features of a rapidly progressing breast cancer in Tunisia.

F Tabbane, L Muenz, M Jaziri, M Cammoun, S Belhassen, N Mourali.   

Abstract

Clinical and radiographic examination of 581 patients with histologically verified breast cancer has permitted us to define a subgroup having a significantly poorer prognosis than other patients. Their condition, called "poussée évolutive" (rapidly progressing), is characterized by rapid tumor growth and/or inflammation adjacent to the tumor. Statistical analysis of the survival of M0 patients (412 of the 581) shows that the diagnosis of "poussée évolutive" provides prognostic information beyond that given by T and N classifications and after delay between initial symptoms and diagnosis have been considered. Six years of clinical experience with this condition are discussed.

Entities:  

Mesh:

Year:  1977        PMID: 880564     DOI: 10.1002/1097-0142(197707)40:1<376::aid-cncr2820400153>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.

Authors:  Tamer M Fouad; Angelica M Gutierrez Barrera; James M Reuben; Anthony Lucci; Wendy A Woodward; Michael C Stauder; Bora Lim; Sarah M DeSnyder; Banu Arun; Babiera Gildy; Vicente Valero; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Lancet Oncol       Date:  2017-04       Impact factor: 41.316

Review 2.  Inflammatory breast cancer clusters: A hypothesis.

Authors:  Paul H Levine; Salman Hashmi; Ashley A Minaei; Carmela Veneroso
Journal:  World J Clin Oncol       Date:  2014-08-10

3.  Breast cancer in women under 30 years of age.

Authors:  F Tabbane; A el May; M Hachiche; J Bahi; M Jaziri; M Cammoun; N Mourali
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

4.  Breast cancer characteristics at diagnosis and survival among Arab-American women compared to European- and African-American women.

Authors:  Sharon Hensley Alford; Kendra Schwartz; Amr Soliman; Christine Cole Johnson; Stephen B Gruber; Sofia D Merajver
Journal:  Breast Cancer Res Treat       Date:  2008-04-15       Impact factor: 4.872

5.  Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas.

Authors:  F Fina; S Romain; L Ouafik; J Palmari; F Ben Ayed; S Benharkat; P Bonnier; F Spyratos; J A Foekens; C Rose; M Buisson; H Gérard; M O Reymond; J M Seigneurin; P M Martin
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

6.  Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation.

Authors:  Vinita Takiar; Catherine L Akay; Michael C Stauder; Welela Tereffe; Ricardo H Alvarez; Karen E Hoffman; George H Perkins; Eric A Strom; Thomas A Buchholz; Naoto T Ueno; Gildy Babiera; Wendy A Woodward
Journal:  Springerplus       Date:  2014-03-31

7.  Preliminary results of primary systemic chemotherapy in association with surgery or radiotherapy in rapidly progressing breast cancer.

Authors:  N Mourali; F Tabbane; L R Muenz; J Bahi; S Belhassen; L S Kamaraju; P H Levine
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

8.  What is inflammatory breast cancer? Revisiting the case definition.

Authors:  Paul H Levine; Ladan Zolfaghari; Heather Young; Muhannad Hafi; Timothy Cannon; Chitra Ganesan; Carmela Veneroso; Rachel Brem; Mark Sherman
Journal:  Cancers (Basel)       Date:  2010-03-03       Impact factor: 6.639

9.  Breast cancer by age at diagnosis in the Gharbiah, Egypt, population-based registry compared to the United States Surveillance, Epidemiology, and End Results Program, 2004-2008.

Authors:  Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; Joe B Harford; Ahmed Hablas; Mohamed Ramadan; Ibrahim Seifeldin; Sofia D Merajver
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.